Loading stock data…
EBS
$8.47+0.24 (+2.92%)
Market ClosedLast close May 1
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Emergent BioSolutions Inc. in the Healthcare sector is trading at $8.47. The stock is currently 40% below its 52-week high of $14.06, remaining 11.8% below its 200-day moving average. Technical signals show neutral RSI of 54 and bullish MACD crossover, explaining why EBS maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 54) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.47
Potential Upside
161.8%
Whystock Fair Value$22.18
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commerc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$429.18M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
8.91
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.36
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
26.69%
Volume
Today's trading volume
1.41M
Recent News
Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved
Emergent Biosolutions (NYSE:EBS) on Tuesday held its 2026 Annual Meeting of Stockholders, where shareholders voted on director elections, auditor ratification, executive compensation, and an amendment to increase shares available under the company’s stock incentive plan. Management also reviewed pro
Emergent BioSolutions Inc. Q1 2026 Earnings Call Summary
Moby summary of Emergent BioSolutions Inc.'s Q1 2026 earnings call
Emergent Biosolutions Q1 Earnings Call Highlights
Emergent Biosolutions (NYSE:EBS) reported first-quarter 2026 results that management said exceeded the high end of the company’s revenue guidance range, while continuing to emphasize progress on a multi-year transformation plan and balance sheet actions completed in April. First-quarter results top
Emergent BioSolutions Inc (EBS) Q1 2026 Earnings Call Highlights: Strong Revenue and Strategic ...
Emergent BioSolutions Inc (EBS) surpasses revenue expectations and strengthens financial position, while navigating pricing pressures and geopolitical risks.
How The Emerging Narrative On Emergent BioSolutions (EBS) Is Shifting After The Earnings Miss
The consensus price target for Emergent BioSolutions has shifted from US$15 to US$12, with the modeled fair value sitting at US$12 per share. Analysts link this move to reduced earnings expectations following the earnings miss, while still keeping a broadly constructive stance on the shares. As you read on, you will see how both bullish and bearish voices are shaping the evolving narrative around this stock and what that might mean for your own view. Analyst Price Targets don't always capture...